Ovarian cancer screening
- PMID: 12959188
- DOI: 10.1016/s0889-8588(03)00063-7
Ovarian cancer screening
Abstract
In an ongoing effort to design an efficacious, cost-effective ovarian cancer screening method, the existing tests, CA 125 and transvaginal sonography, are being optimized and combined in a multimodal strategy, and new promising serum markers, such as mesothelin and HE4, are being developed and evaluated. Detection has been found to improve when multiple serum markers are used in a longitudinal logarithm. The parametric empirical Bayes approach improves screening algorithms by capturing the stability of markers over time in a heterogeneous population. It also has relatively simple extensions to multiple markers. The evaluation of markers increasingly accounts for characteristics of a woman that may affect her marker levels and accounts for the cancer's characteristics, histology, and grade. Receiver operating characteristic curves are helpful for evaluation because they relate a marker's sensitivity to the specificity at which it operates. Large, well-designed randomized controlled trials are under way to gauge the performance of existing screening methods.
Similar articles
-
Elevation of multiple serum markers in patients with stage I ovarian cancer.J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51. doi: 10.1093/jnci/85.21.1748. J Natl Cancer Inst. 1993. PMID: 8411259
-
Combined use of biomarkers for detection of ovarian cancer in high-risk women.Tumour Biol. 2010 Jun;31(3):209-15. doi: 10.1007/s13277-010-0032-x. Tumour Biol. 2010. PMID: 20393825
-
New tumor markers: CA125 and beyond.Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. doi: 10.1111/j.1525-1438.2005.00441.x. Int J Gynecol Cancer. 2005. PMID: 16343244 Review.
-
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.J Clin Oncol. 2004 Oct 15;22(20):4059-66. doi: 10.1200/JCO.2004.03.091. Epub 2004 Sep 20. J Clin Oncol. 2004. PMID: 15381683
-
Status of tumor markers in ovarian cancer screening.J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s. doi: 10.1200/JCO.2003.01.068. J Clin Oncol. 2003. PMID: 12743135 Review.
Cited by
-
Molecular Management of High-Grade Serous Ovarian Carcinoma.Int J Mol Sci. 2022 Nov 9;23(22):13777. doi: 10.3390/ijms232213777. Int J Mol Sci. 2022. PMID: 36430255 Free PMC article. Review.
-
Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?Biomedicines. 2022 Aug 29;10(9):2113. doi: 10.3390/biomedicines10092113. Biomedicines. 2022. PMID: 36140214 Free PMC article. Review.
-
The temporal stability of the Symptom Index among women at high-risk for ovarian cancer.Gynecol Oncol. 2009 Aug;114(2):225-30. doi: 10.1016/j.ygyno.2009.03.015. Epub 2009 May 7. Gynecol Oncol. 2009. PMID: 19427026 Free PMC article.
-
Protein biomarkers of ovarian cancer: the forest and the trees.Future Oncol. 2012 Jan;8(1):55-71. doi: 10.2217/fon.11.135. Future Oncol. 2012. PMID: 22149035 Free PMC article. Review.
-
Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.Tumour Biol. 2012 Oct;33(5):1335-9. doi: 10.1007/s13277-012-0381-8. Epub 2012 Apr 13. Tumour Biol. 2012. PMID: 22528938
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials